Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

Sakura, Hiroshi; Hashimoto, Naotake; Sasamoto, Kazuo; Ohashi, Hiroshi; Hasumi, Sumiko; Ujihara, Noriko; Kasahara, Tadasu; Tomonaga, Osamu; Nunome, Hideo; Honda, Masashi; Iwamoto, Yasuhiko

doi:10.1186/s12902-016-0149-z

Table 2 Laboratory test results

From: Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

Parameter	n	0 month (mean ± SE)	n	3 months (mean ± SE) ∆3 months, mean (95% CI)	p	n	12 months (mean ± SE) ∆12 months, mean (95% CI)	p
HbA1c	649	7.86 ± 0.04	635 634	7.12 ± 0.04 −0.73 (−0.80, −0.67)	0.001>	577 576	7.11 ± 0.04 −0.69 (−0.76, −0.62)	0.001>
Converted mean HbA1c(mmol/mol)		62		54			54
Fasting blood glucose	493	159.2 ± 1.9	446 413	135.1 ± 1.6 −26.3 (−29.7, −22.9)	0.001>	394 361	135.9 ± 1.7 −23.2 (−27.3, −19.2)	0.001>
HOMA-R	384	2.83 ± 0.09	367 318	2.71 ± 0.14 −0.36 (−0.51, −0.22)	0.001>	331 275	2.66 ± 0.11 −0.29 (−0.47, −0.10)	0.002
HOMA-β	382	32.1 ± 1.4	364 315	47 ± 3.2 11.5 (8.4, 14.6)	0.001>	324 270	43.9 ± 2 11.1 (7.6, 14.6)	0.001>
Fasting insulin	384	7.22 ± 0.21	367 318	8.09 ± 0.43 0.21 (−0.15, 0.57)	0.254	331 275	7.77 ± 0.29 0.29 (−0.10, 0.67)	0.147
1.5AG	254	6.4 ± 0.3	248 240	11.3 ± 0.4 4.8 (4.3, 5.2)	0.001>	213 207	10.2 ± 0.4 3.8 (3.2, 4.3)	0.001>
Glycoalbumin	254	21.1 ± 0.2	248 240	18.2 ± 0.2 −2.7 (−3.1, −2.4)	0.001>	213 207	18.5 ± 0.2 −2.5 (−2.9, −2.2)	0.001>
C-Peptide	200	2.1 ± 0.06	197 177	2.07 ± 0.06 0 (−0.11, 0.1)	0.925	152 137	2.17 ± 0.08 0.05 (−0.06, 0.15)	0.380
Proinsulin-to-insulin ratio	193	0.51 ± 0.02	187 169	0.45 ± 0.02 −0.05 (−0.08, −0.02)	0.033	150 135	0.49 ± 0.02 −0.01 (−0.05, 0.03)	0.857
CPI	200	1.38 ± 0.05	197 177	1.56 ± 0.05 0.23 (0.15, 0.32)	0.001>	152 137	1.66 ± 0.07 0.28 (0.18, 0.38)	0.001>
SBP	646	130.9 ± 0.6	635 634	129.3 ± 0.6 −1.7 (−2.9, −0.6)	0.004	576 575	130.2 ± 0.6 −0.3 (−1.6, 0.9)	0.587
DBP	646	76.5 ± 0.4	635 634	75.3 ± 0.4 −1.2 (−1.9, −0.4)	0.003	576 575	75.6 ± 0.4 −0.9 (−1.7, −0.1)	0.022
BMI	630	25.19 ± 0.17	601 599	25.24 ± 0.17 0 (−0.10, 0.05)	0.987	552 549	25.1 ± 0.18 −0.08 (−0.20, 0)	0.064
Triglycerides	589	149.3 ± 4.1	569 551	146.7 ± 5.1 −6.1 (−13.0, 0.7)	0.081	537 517	142.5 ± 4.2 −8.9 (−16.0, −1.3)	0.021
HDL-C	574	55 ± 0.6	555 537	53.8 ± 0.6 −1.1 (−1.8, −0.5)	0.001	527 506	53.6 ± 0.6 −1.6 (−2.3, −0.9)	0.001>
LDL-C	589	113.9 ± 1.2	563 545	110 ± 1.2 −3.2 (−4.9, −1.5)	0.001>	533 512	110.3 ± 1.2 −3.4 (−5.6, −1.2)	0.003

Upper row: Observed value (mean ± SE)
Lower row: Change (mean [95% CI])
p-value: versus 0 month, paired t-test

Back to article page

ISSN: 1472-6823

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Endocrine Disorders

Contact us